Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter and Full Year 2024 Results Call. All participants will be in listen-only ...

Before diving into the highlights '24, we did put on the 20 years Molecular Partners logo because it is our ... we bring the vector, but we still need access to an isotope. And isotope supply ...

Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific ...

Goldman Sachs initiated coverage of Sanofi (SNY) with a Neutral rating and $65 price target While the firm sees Sanofi emerging as a pipeline story, it believes this is somewhat reflected at ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologics’ novel immune checkpoint inhibitor, the French pharma is handing the prospect back to Biond. The move is due ...

Sanofi India share price gains were likely driven by its quarterly results performance and the dividend announcements, even though stock gave away most gains as the stock market crashed and Sensex ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

Shares of Sanofi India gained above 4 percent in early trade on February 28 following its Q4FY25 earnings, as the company reported healthy revenue growth even as profitability faced some ...

Sanofi said it would acquire Bispecific Myeloid Cell Engager, an autoimmune disease treatment, from Dren Bio, for up to $1.9 billion. The French pharmaceutical company on Thursday said it would ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

March 4 (Reuters) - South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority ...